Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will determine if individuals with co-occurring bipolar disorder and alcohol dependence report reduced alcohol consumption, improvement in mood symptoms, and cognitive performance if treated with lamotrigine plus their usual mood stabilizing medications relative to subjects treated with placebo plus usual mood stabilizing medications over a 16 week period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of South Carolina
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Anticonvulsants; Ethanol; Lamotrigine

Criteria

Inclusion Criteria:

• Age 18-65

• Meet DSM-IV-TR criteria for current alcohol dependence with active alcohol use in the past 30 days

• Meet DSM-IV-TR criteria for bipolar I or bipolar II disorder

• Have average alcohol consumption of at least 35 drinks/week for men, 28 drinks/week for women in the last 4 weeks of active drinking prior to enrollment.

• Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of the assessment instruments.

• Must consent to random assignment and be willing to commit to medication treatment and follow-up assessments.

• Currently under the care of a psychiatrist.

• Must consent to sign a release of information allowing investigators to communicate with his/her psychiatrist to verify treatment history and facilitate care should treatment-emergent psychiatric symptoms develop during the trial.

• Currently taking a therapeutic dosage of one or more mood stabilizing medications as defined by one or more of the following:

• Lithium level of 0.6 - 1.2 mEq/L

• Prescribed daily use of first generation antipsychotic agents including chlorpromazine, fluphenazine, or haloperidol or their injectible depot (decanoate) equivalents at a dose adequate to maintain clinical stability as documented by the subject's outpatient psychiatric provider c) Prescribed daily use of second generation antipsychotic agents including olanzapine, risperidone, paliperidone, quetiapine, aripiprazole, or ziprasidone or their injectible depot equivalent at a dose adequate to maintain clinical stability as documented by the subject's outpatient psychiatric provider

• Stable psychiatric symptoms as defined by no changes to psychotropic drug regimen for 30 days

• Must agree to identify collateral individuals for contact to facilitate follow-up appointments

Exclusion Criteria:

• A primary psychiatric diagnosis other than bipolar disorder

• Any uncontrolled neurologic condition (e.g. epilepsy) that could confound the results of the study

• Any history of Stevens-Johnson syndrome or other severe rash requiring hospitalization

• Any history of head injury with loss of consciousness greater than 30 minutes

• Any history of learning disability, alcoholic dementia, or electroconvulsive therapy in the past 3 months

• Any uncontrolled medical condition that may adversely affect the conduct of the trial or jeopardize the safety of the subject

• Plasma levels of liver transaminases (AST, ALT) greater than 3 times the normal range

• Concomitant use of valproic acid

• Concomitant use of carbamazepine, oxcarbazepine, phenytoin, primidone, or phenobarbital

• Concomitant use of disulfiram, naltrexone, acamprosate, or topiramate

• Concomitant use of benzodiazepines or any other medications not allowed per the protocol

• Women of childbearing potential who are pregnant, lactating, or refuse adequate forms of contraception

• Current suicidal or homicidal risk

• Baseline scores of more than 35 on the Montgomery-Asberg Depression Rating Scale or more than 16 on the Young Mania Rating Scale